BMS-214662

DB12234InvestigationalSmall molecule

BMS-214662 has been used in trials studying the treatment of Childhood Myelodysplastic Syndromes, Refractory Anemia With Excess Blasts, Recurrent Adult Acute Myeloid Leukemia, Relapsing Chronic Myelogenous Leukemia, and Adult Acute...

Formula / weight: C₂₅H₂₃N₅O₂S₂ · 489.612 g/mol (avg)
Code names: BMS-214662

Resolves to

Compound

UNIIL2U9GFD244CAS195987-41-8ChEMBLCHEMBL351706PubChem448545

Structure

InChIKeyOLCWFLWEHWLBTO-HSZRJFAPSA-NSMILES[H][C@@]1(CC2=CC=CC=C2)CN(CC2=CN=CN2)C2=C(CN1S(=O)(=O)C1=CC=CS1)C=C(C=C2)C#N

Targets

P49356FNTBP49354FNTA

What you can answer from here — as of August 30, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with BMS-214662, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account